Formulation and Drug Delivery, Specialty Dosage Forms

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers as part of AstraZeneca’s Ambition Zero Carbon program.

ImmunityBio will proceed with a Phase I/II/III trial in South Africa of their dual-antigen T-cell vaccine as a boost in participants who were previously vaccinated against COVID-19.

UltraBurst has a high disintegration speed, which is for all market segments, from prescriptions to nutraceuticals.

Modified-release dosage forms present new opportunities for drug developers and can help overcome challenges, such as short biological half-life or poor bioavailability due to degradation in the stomach.

Aprecia and Glatt investigate manufacturing technologies to widen the formulation design space for oral delivery.

Equipment and process optimization must be considered for scaling up these developmental technologies to commercial production.

The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.

Research examined the effects of varying excipient and polymer weight in coatings designed to optimize the release of diclofenac sodium. The goal was to release it at night to improve the treatment of rheumatoid arthritis.

PATH’s Microarray Patch Center of Excellence aims to accelerate transdermal patch technology for public health needs.

Cure Pharmaceutical secured a patent that lets the company load higher drug amounts to its proprietary drug delivery system, CUREfilm.

Wearable and smart devices allow user-friendly subcutaneous drug delivery.

Regulatory, cultural, and technical differences between drug and device development can pose challenges to pharmaceutical combination product development.

Intertek has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, UK, through the acquisition of a new 20,000 sq. ft facility.

Understanding the API, delivery mechanism, and excipient functionality is essential to solving drug solubility challenges.

STA Pharmaceuticals and BioLingus have announced the formation of an exclusive technology and marketing collaboration for sublingual delivery.

Transdermal patch design, materials, and manufacturing variables, as well as drug formulation and interactions between the API and the adhesive, can affect adhesion and drug delivery.

Virpax’s Patch-in-a-Can technology delivers pain medication using a metered-dose spray film.

Drug and adhesive formulation are crucial to the development of microneedle patches for pharmaceutical transdermal delivery systems.

Funding from Innovate UK will be used by Medherant to support manufacture of transdermal patches for clinical trials.

Innovative technologies, such as drug-loaded devices and 3D printing, enable advances in implantable devices and other novel dosage forms.

The human skin protects the body from physical, mechanical, and chemical insults while preventing endogenous water loss. This function is predominantly achieved by a thin (10–30 µm) cornified outermost layer-the stratum corneum (SC)-generated through terminal differentiation of the basal epidermal keratinocytes. The stratum corneum protects the human body, but also severely limits drug delivery into and across the skin.

Pharmaceutical companies are developing new strategies to address the ever-increasing development costs for new drug therapies and maximize the value of their existing drug portfolio.

API can be mixed with silicone and other polymers to create drug-delivery combination products.

With the right excipients, formulators can control when, where, and how an API is released.

The CUREfilm technology delivers drugs through a dissolvable strip that can be applied in the oral cavity or onto the skin.

Choice of carrier can have a significant impact on the capsule filling process as well as the performance of the DPI formulation.

Particle engineering using jet milling or spray drying can be used to obtain appropriate particle characteristics for inhalation drug products.

Puncture and aerosolization tests measure the effectiveness of hard-shell capsules used in dry powder inhalers (DPIs) for inhaled drug products.

Case studies compare efficacy testing of preservatives for topical formulations with probiotic actives.

Aston Particle Technologies has developed a technology that produces functionalized particles in a one-step, environmentally friendly process.